Latest News
& Press Releases

Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.

Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.

Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.

Genentech has exercised the second option in its potentially $1.7 billion agreement with Bicycle Therapeutics, triggering a $10 million payment.

Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.

Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.

Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.

Flagship Pioneering has launched Apriori Bio, which utilizes artificial intelligence to predict virus activity and variant formation, including COVID-19.

uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.

Exelixis’ Cabometyx, in combination with two BMS-owned drugs, hit the primary endpoint of progression-free survival but missed the secondary endpoint of overall survival in renal cell carcinoma.

Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.

Vertex Pharmaceuticals plans to acquire ViaCyte for $320 million in cash. ViaCyte focuses on stem cell-derived cell replacement therapies that they hope will cure type 1 diabetes (T1D).

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories.

• $5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027 • $4.5 million of accrued VAT refunds and R&D refundable tax credits from UK subsidiary begin maturing, including $1.9 million VAT cash refund expected in June 2026 • Successful EMA and Australia TGA (ATGA) meetings aligned around use of existing biomarker and pending release of 3-year overall survival data to support Conditional Marketing Authorisations (CMAs) for OST-HER2 in prevention or delay of recurrence in fully-resected, pulmonary metastatic osteosarcoma (“Metastatic Osteosarcoma”) • 2.5-year overall survival data expected to be released during ASCO 2026 • EMA and ATGA have aligned on key design aspects of confirmatory Phase 3 Metastatic Osteosarcoma protocol required to have commenced prior to grant of CMAs or FDA BLA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint • Upcoming U.S. FDA Type C meeting and U.K. MHRA SAM meeting to align with EMA & ATGA prior to Australia Clinical Trial Notification submission for Phase 3, including alignment on 3-year overall survival as a primary clinical efficacy endpoint. U.S. FDA (“FDA”) Pre-BLA meeting to confirm alignment on surrogate and primary clinical efficacy endpoints with EMA/ATGA, including alignment on 3-year overall survival as a primary clinical efficacy endpoint, and seek decisions on rolling review acceptance and RMAT designation following the EMA and U.K. MHRA granting ATMP designation (EMA/MHRA RMAT equivalent) for OST-HER2 in Metastatic Osteosarcoma • OS Animal Health S-1 filing for proposed ‘Go-Public’ transaction and receipt of SEC comments